Corticosteroid News and Research

Corticosteroids are any steroid hormones made in the adrenal cortex (the outer part of the adrenal gland). They are also made in the laboratory. Corticosteroids have many different effects in the body, and are used to treat many different conditions. They may be used as hormone replacement, to suppress the immune system, and to treat some side effects of cancer and its treatment. Corticosteroids are also used to treat certain lymphomas and lymphoid leukemias.

Soligenix receives $9.4M NIAID grant to develop technology for advancing rapidly acting vaccines

20. November 2009 07:45

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has formed a consortium to develop thermostable technology to advance RiVax(TM) and other rapidly acting vaccines. Soligenix received a $9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to support this work. [More]

25d5bf3a-1a13-4ddf-befb-b2fa1aaa7721|0|.0

Posted in: Device / Technology News | Pharmaceutical News

Tags: Allergy, Anthrax, Beclomethasone, Biotechnology, Cancer, Cell, Corticosteroid, Drug Delivery, Endometriosis, Prostate Cancer, Vaccine

Phase II clinical study to evaluate Nanocort commenced

17. November 2009 03:22

Galapagos NV announced today that it has started a Phase II clinical study to evaluate Nanocort's effectiveness in treating flares in multiple sclerosis (MS). Nanocort combines less frequent treatment with lower dosage and potentially more effective delivery than other MS flare treatments. [More]

c671443c-7394-49e8-a18e-5988be78afd0|0|.0

Posted in: Drug Trial News

Tags: Antibody, Arthritis, Autoimmune Disease, Bone, Brain, Corticosteroid, Liposome, Metastasis, Multiple Sclerosis, Myelin, Nervous System, Rheumatoid Arthritis, Steroid

Third quarter 2009 financial results announced by Soligenix

13. November 2009 07:36

Soligenix, Inc., (Soligenix or the Company) (OTC Bulletin Board: SNGX), formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today its financial results for the third quarter of 2009. [More]

0b7889c9-dd34-4401-ba2f-1ebfb694c8ec|0|.0

Posted in: Business / Finance

Tags: Allergy, Beclomethasone, Biotechnology, Cancer, Cell, Corticosteroid, Drug Delivery, Endometriosis, Prostate Cancer, Vaccine

Canadian researchers organize several clinical trials to find new treatments for H1N1 infection

12. November 2009 04:15

An important, ground-breaking initiative is unfolding in the global critical care community in response to the H1N1 pandemic. [More]

ecb61b29-6d2b-4f07-81cd-1aebe5542dee|0|.0

Posted in: Disease/Infection News | Pharmaceutical News

Tags: Cancer, Cholesterol, Corticosteroid, Diabetes, Education, H1N1, Hospital, Influenza, Intensive Care, Neurosurgery, Pandemic, Trauma, Vaccine, Ventilator

Shire reports results of Lialda and 5-ASA persistency analyses

27. October 2009 04:43

Shire plc, the global specialty biopharmaceutical company, presented the results of three 5-aminosalicylic acid (5-ASA) persistency analyses at ACG 2009 Annual Scientific Meeting, evaluating persistency of Lialda® (mesalamine), Asacol® (mesalamine), Pentasa® (mesalamine) (250mg and 500mg), balsalazide [combined results from generic balsalazide disodium and Colazal® (balsalazide disodium)], and Dipentum® (olsalazine sodium) (500mg). [More]

6a09e06b-7bbd-4d0b-aab4-4897c509bcbe|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Corticosteroid, Hypersensitivity, Inflammatory Bowel Disease, Salicylates, Stenosis, Ulcerative Colitis

Difficult-to-treat asthma may be attributed to poor medication adherence

26. October 2009 00:30

Difficult-to-treat asthma often may have more to do with patients who do not take their medication as instructed than ineffective medication, according to researchers in Northern Ireland. [More]

a6988475-c151-408c-97d8-cb1334eb44c0|1|5.0

Posted in: Medical Condition News

Tags: Asthma, Corticosteroid, Cortisol, Hospital

Non-adherence to medication may be the cause for difficult asthma

23. October 2009 01:09

Difficult-to-treat asthma often may have more to do with patients who do not take their medication as instructed than ineffective medication, according to researchers in Northern Ireland. [More]

0fe8dba5-d5a7-4f12-bb2a-773a607577d8|0|.0

Posted in: Medical Condition News

Tags: Asthma, Corticosteroid, Cortisol, Hospital

Schering-Plough announces 2009 third quarter financial results

22. October 2009 07:05

Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2009 third quarter. [More]

f483d376-a40f-47e5-be09-6dd38dd1f39b|0|.0

Posted in: Business / Finance

Tags: Anesthesiology, Ankylosing Spondylitis, Antihistamine, Arthritis, Asenapine, Asthma, Brain, Cholesterol, Corticosteroid, Crohn's Disease, Estradiol, Fertility, Generic Drug, Golimumab, Hepatitis C, Influenza, Melanoma, New Drug Application, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Schizophrenia, Ulcerative Colitis, Vaccine, Vicriviroc, Vytorin

Lux Biosciences to present on LX211 at 2009 AAO annual conference

21. October 2009 08:46

Lux Biosciences, Inc., a privately held biotechnology company focused on the development and commercialization of therapies for serious ophthalmic diseases, today announced that the company’s experimental drug LX211 (LUVENIQ; oral voclosporin) will be featured in several presentations at the 2009 American Academy of Ophthalmology annual conference and American Uveitis Society meeting being held October 24-26 in San Francisco. [More]

b6c28621-c72c-48f3-8e94-99d47f011aa3|0|.0

Posted in: Pharmaceutical News

Tags: Biotechnology, Corticosteroid, Exercise, Hospital, Immunology, Ophthalmology, Steroid, Uveitis

Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD

15. October 2009 07:52

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated enrollment in its confirmatory Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial evaluating orBec(®) for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD). [More]

e238801d-f2fd-4cb0-9da5-261aee505813|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Anorexia, Asthma, Beclomethasone, Biotechnology, Bone, Bone Marrow, Cancer, Cell, Corticosteroid, Diarrhea, Drug Delivery, Endometriosis, Nausea, New Drug Application, Oncology, Prostate Cancer, Rhinitis, Stem Cell, Transplant, Vaccine, Vomiting

Triple therapy may benefit patients with chronic obstructive pulmonary disease

8. October 2009 03:11

Patients with moderate to severe chronic obstructive pulmonary disease (COPD) can benefit from triple therapy that includes a long-acting β-agonist (LABA), an inhaled corticosteroid (ICS) and an anti-muscarinic agent, according to researchers in Germany. [More]

a86162c4-60ff-49da-9816-c57a54a5fe7f|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Corticosteroid

pSivida reports interim results of human PK study of Iluvien

29. September 2009 08:49

pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien. [More]

29d2055b-db2d-4035-97dd-b98448217a95|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Biotechnology, Cancer, Corticosteroid, Cytomegalovirus, Diabetic Macular Edema, Drug Delivery, Edema, Exercise, Pancreatic Cancer, Pfizer, Steroid, Uveitis

DOR Biopharma to raise $3.85 million from institutional investors

25. September 2009 09:15

DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biotechnology company, announced today that it has entered into common stock purchase agreements with institutional investors totaling approximately $3.85 million. DOR's North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this financing. [More]

c95ea01c-32d1-421d-8b69-1fe5871dffdd|0|.0

Posted in: Business / Finance

Tags: Beclomethasone, Biotechnology, Cancer, Cell, Corticosteroid, Drug Delivery, Endometriosis, Prostate Cancer, Vaccine

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

21. September 2009 08:10

Data published today in The Lancet showed a survival benefit in nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who received maintenance therapy with ALIMTA(R) (pemetrexed for injection) plus best supportive care as compared to placebo plus best supportive care. [More]

b6cbe3ec-e205-4495-a0fc-66997bfc97d4|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Alimta, Anemia, Anorexia, Anti-Inflammatory, Birth Control, Bone, Bone Marrow, Cancer, Cell, Chemotherapy, Cisplatin, Constipation, Contraception, Corticosteroid, Diarrhea, Folic Acid, Lung Cancer, Mesothelioma, Nausea, Neuropathy, Neutropenia, Non-Small Cell Lung Cancer, Nursing, Oncology, Pemetrexed, Pregnancy, Small Cell Lung Cancer, Squamous Cell Carcinoma, Vomiting

NIAID awards DOR BioPharma a $9M grant to develop thermostable and rapidly acting vaccines

21. September 2009 07:42

DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that it has been awarded an approximate $9.4 Million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH). [More]

80153d35-0672-4bda-a7f1-57b069ae3b91|0|.0

Posted in: Pharmaceutical News

Tags: Allergy, Anthrax, Antibody, Beclomethasone, Biotechnology, Cancer, Cell, Corticosteroid, Drug Delivery, Endometriosis, Prostate Cancer, Vaccine

<< Previous posts

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.

Free!

Recent Comments

Twitter

Information

Corticosteroid News and Research

Soligenix receives $9.4M NIAID grant to develop technology for advancing rapidly acting vaccines

Phase II clinical study to evaluate Nanocort commenced

Third quarter 2009 financial results announced by Soligenix

Canadian researchers organize several clinical trials to find new treatments for H1N1 infection

Shire reports results of Lialda and 5-ASA persistency analyses

Difficult-to-treat asthma may be attributed to poor medication adherence

Non-adherence to medication may be the cause for difficult asthma

Schering-Plough announces 2009 third quarter financial results

Lux Biosciences to present on LX211 at 2009 AAO annual conference

Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD

Triple therapy may benefit patients with chronic obstructive pulmonary disease

pSivida reports interim results of human PK study of Iluvien

DOR Biopharma to raise $3.85 million from institutional investors

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

NIAID awards DOR BioPharma a $9M grant to develop thermostable and rapidly acting vaccines

Recent Articles

Free!

Recent Comments

Twitter

Information

Corticosteroid News and Research

Medical News Cloud

Recent Articles